Osteonecrosis of the jaw - Who gets it, and why?

Bone

Volumn 44, Issue 1, 2009, Pages 4-10

  Reid, Ian R ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Bisphosphonate; Cancer; Osteoporosis

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; IBANDRONIC ACID; PAMIDRONIC ACID; RISEDRONIC ACID; ZOLEDRONIC ACID;

BIOFILM; BONE METASTASIS; BONE NECROSIS; BONE TURNOVER; BREAST CANCER; CANCER PATIENT; CHRONIC DISEASE; CLINICAL PRACTICE; COMPUTER ASSISTED TOMOGRAPHY; DENTIST; DENTISTRY; DOSAGE SCHEDULE COMPARISON; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG WITHDRAWAL; HISTOLOGY; HUMAN; INCIDENCE; INFECTION; ISCHEMIA; JAW DISEASE; MANDIBLE; MAXILLA; MYELOMA; OSTEOMYELITIS; OSTEOPOROSIS; PATHOGENESIS; PORPHYROMONAS GINGIVALIS; PRACTICE GUIDELINE; PREVALENCE; PROSTATE CANCER; REVIEW; RISK REDUCTION; SCANNING ELECTRON MICROSCOPY; SOFT TISSUE; TOOTH EXTRACTION;

DIPHOSPHONATES; HUMANS; ISCHEMIA; JAW DISEASES; NEOPLASMS; OSTEONECROSIS; OSTEOPOROSIS;

EID: 57549103742     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2008.09.012     Document Type: Review

References (65)

1. Khosla S., Burr D., Cauley J., Dempster D.W., Ebeling P.R., Felsenberg D., et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J. Bone Mineral Res. 22 (2007) 1479-1491
2. American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J. Oral Maxillofac. Surg. 65 (2007) 369-376
3. Khosla S., Burr D., Cauley J., Dempster D.W., Ebeling P.R., Felsenberg D., et al., American Society for Bone and Mineral R. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J. Bone Mineral Res. 22 (2007) 1479-1491
4. Abu-Id M.H., Warnke P.H., Gottschalk J., Springer I., Wiltfang J., Acil Y., et al. Bis-phossy jaws" - high and low risk factors for bisphosphonate-induced osteonecrosis of the jaw. J. Cranio-Maxillofac. Surg. 36 (2008) 95-103
5. Felsenberg D., Hoffmeister B., and Amling M. Kiefernekrosen nach hoch dosierter Bisphosphonattherapie. Dtsch. Ärztebl. 103 (2006) 3078-3081
6. Fugazzotto P.A., Lightfoot W.S., Jaffin R., and Kumar A. Implant placement with or without simultaneous tooth extraction in patients taking oral bisphosphonates: postoperative healing, early follow-up, and the incidence of complications in two private practices. J. Periodontol. 78 (2007) 1664-1669
7. Bell B.M., and Bell R.E. Oral bisphosphonates and dental implants: a retrospective study. J. Oral Maxillofac. Surg. 66 (2008) 1022-1024
8. Grant B.T., Amenedo C., Freeman K., and Kraut R.A. Outcomes of placing dental implants in patients taking oral bisphosphonates: a review of 115 cases. J. Oral Maxillofac. Surg. 66 (2008) 223-230
9. Jeffcoat M.K. Safety of oral bisphosphonates: controlled studies on alveolar bone. Int. J. Oral Maxillofac. Implants 21 (2006) 349-353
10. Wessel J.H., Dodson T.B., and Zavras A.I. Zoledronate, smoking, and obesity are strong risk factors for osteonecrosis of the jaw: a case-control study. J. Oral Maxillofac. Surg. 66 (2008) 625-631
11. Khamaisi M., Regev E., Yarom N., Avni B., Leitersdorf E., Raz I., et al. Possible association between diabetes and bisphosphonate-related jaw osteonecrosis. J. Clin. Endocrinol. Metab. 92 (2007) 1172-1175
12. Hoff A.O., Toth B.B., Altundag K., Guarneri V., Adamus A., Nooka A.K., Sayegh G.G., Johnson M.M., Gagel R.F., and Hortobagyi G.N. Osteonecrosis of the jaw in patients receiving intravenous bisphosphonate therapy. J. Clin. Oncol. 24 suppl (2006) 8528
13. Durie B.G.M., Katz M., and Crowley J. Osteonecrosis of the jaw and bisphosphonates. N. Engl. J. Med. 353 (2005) 99-100
14. Cafro A.M. Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: definition and management of the risk related to zoledronic acid. Clin. Lyphoma. Myeloma. 8 (2008) 111-116
15. Wilkinson G.S., Kuo Y.F., Freeman J.L., and Goodwin J.S. Intravenous bisphosphonate therapy and inflammatory conditions or surgery of the jaw: a population-based analysis. J. Natl. Canc. Inst. 99 (2007) 1016-1024
16. Cartsos V.M., Zhu S., and Zavras A.I. Bisphosphonate use and the risk of adverse jaw outcomes. JADA 139 (2008) 23-30
17. Yarom N., Yahalom R., Shoshani Y., Hamed W., Regev E., and Elad S. Osteonecrosis of the jaw induced by orally administered bisphosphonates: incidence, clinical features, predisposing factors and treatment outcome. Osteoporos. Int. 18 (2007) 1363-1370
18. Black D.M., Delmas P.D., Eastell R., Reid I.R., Boonen S., Cauley J.A., Cosman F., Lakatos P., Leung P.C., Man Z., Mautalen C., Mesenbrink P., Hu H.L., Caminis J., Tong K., Rosario-Jansen T., Krasnow J., Hue T.F., Sellmeyer D., Eriksen E.F., and Cummings S.R. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N. Engl. J. Med. 356 (2007) 1809-1822
19. Grbic J.T., Landesberg R., Lin S.Q., Mesenbrink P., Reid I.R., Leung P.C., et al. Incidence of osteonecrosis of the jaw in women with postmenopausal osteoporosis in the Health Outcomes and Reduced Incidence With Zoledronic Acid Once Yearly Pivotal Fracture Trial. JADA 139 (2008) 32-40
20. Lyles K.W., Colon-Emeric C.S., Magaziner J.S., Adachi J.D., Pieper C.F., Mautalen C., et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N. Engl. J. Med. 357 (2007) 1799-1809
21. Pazianas M., Blumentals W.A., and Miller P.D. Lack of association between oral bisphosphonates and osteonecrosis using jaw surgery as a surrogate marker. Osteoporos. Int. 19 (2008) 773-779
22. Reid I.R., Miller P., Lyles K., Fraser W., Brown J.P., Saidi Y., et al. Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease. N. Engl. J. Med. 353 (2005) 898-908
23. Malmgren B., Atrom E., and Soderhall S. No osteonecrosis in jaws of young patients with osteogenesis imperfecta treated with bisphosphonates. J. Oral Pathol. Med. 37 (2008) 196-200
24. Mavrokokki T., Cheng A., Stein B., Goss A.A.F.N.M.T., Cheng A., Stein B., and Goss A. Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J. Oral Maxillofac. Surg. 65 (2007) 415-423
25. Hansen T., Kunkel M., Weber A., and Kirkpatrick C.J. Osteonecrosis of the jaws in patients treated with bisphosphonates - histomorphologic analysis in comparison with infected osteoradionecrosis. J. Oral Pathol. Med. 35 (2006) 155-160
26. Fournier P., Boissier S., Filleur S., Guglielmi J., Cabon F., Colombel M., and Clezardin P. Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res. 62 (2002) 6538-6544
27. Sedghizadeh P.P., Kumar S.K.S., Gorur A., Schaudinn C., Shuler C.F., and Costerton J.W. Identification of microbial biofilms in osteonecrosis of the jaws secondary to bisphosphonate therapy. J. Oral Maxillofac. Surg. 66 (2008) 767-775
28. Dodson T.B., Raje N.S., Caruso P.A., Rosenberg A.E., Smullin S.E., and Harris N.L. A woman with a nonhealing ulcer of the jaw - Gingival ulceration, inflammation, and acute osteomyelitis with actinomyces, all associated with necrosis of bone (bisphosphonate-related osteonecrosis of bone). N. Engl. J. Med. 358 (2008) 1283-1291
29. Hansen T., Kirkpatrick C.J., Walter C., and Kunkel M. Increased numbers of osteoclasts expressing cysteine proteinase cathepsin K in patients with infected osteoradionecrosis and bisphosphonate-associated osteonecrosis - a paradoxical observation?. Virchows. Archiv. 449 (2006) 448-454
30. Chiandussi S., Biasotto M., Dore F., Cavalli F., Cova M.A., and Di Lenarda R. Clinical and diagnostic imaging of bisphosphonate-associated osteonecrosis of the jaws. Dentomaxillofac. Radiol. 35 (2006) 236-243
31. Bisdas S., Pinho N.C., Smolarz A., Sader R., Vogl T.J., and Mack M.G. Biphosphonate-induced osteonecrosis of the jaws: CT and MRI spectrum of findings in 32 patients. Clin. Radiol. 63 (2008) 71-77
32. Biasotto M., Chiandussi S., Dore F., Rinaldi A., Rizzardi C., Cavalli F., et al. Clinical aspects and management of bisphosphonates-associated osteonecrosis of the jaws. Acta Odontol. Scand. 64 (2006) 348-354
33. Reid I.R., and Cundy T. Osteonecrosis of the jaw. Skelet. Radiol. (2008) (in press)
34. Marx R.E., Cillo J.E., and Ulloa J.J. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J. Oral Maxillofac. Surg. 65 (2007) 2397-2410
35. Reid I.R., Brown J.P., Burckhardt P., Horowitz Z., Richardson P., Trechsel U., et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N. Engl. J. Med. 346 (2002) 653-661
36. Khan S.A., Kanis J.A., Vasikaran S., Kline W.F., Matuszewski B.K., McCloskey E.V., et al. Elimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis. J. Bone Mineral Res. 12 (1997) 1700-1707
37. Skerjanec A., Berenson J., Hsu C., Major P., Miller Jr. W.H., Ravera C., et al. The pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with varying degrees of renal function. J. Clin. Pharmacol. 43 (2003) 154-162
38. Lin J.H., Chen I.W., and Duggan D.E. Effects of dose, sex, and age on the disposition of alendronate, a potent antiosteolytic bisphosphonate, in rats. Drug Metab. Dispos. 20 (1992) 473-478
39. Dixon R.B., Tricker N.D., and Garetto L.P. Bone turnover in elderly canine mandible and tibia. J. Dental Res. 76 (1997) 336
40. Baron R., Saffar J.L., and Duflot-Vignery A. Alveolar bone remodelling in the rat: normal status and effects of PTX and PTH on the remodelling sequence and the osteoclastic pool. Calcif. Tissue Res. 22 Suppl (1977) 502-504
41. Reid I.R., Bolland M.J., and Grey A.B. Is bisphosphonate-associated osteonecrosis of the jaw caused by soft tissue toxicity?. Bone 41 (2007) 318-320
42. Coxon F.P., Thompson K., Roelofs A.J., Ebetino F.H., and Rogers M.J. Visualizing mineral binding and uptake of bisphosphonate by osteoclasts and non-resorbing cells. Bone 42 (2008) 848-860
43. Thompson K., Rogers M.J., Coxon F.P., and Crockett J.C. Cytosolic entry of bisphosphonate drugs requires acidification of vesicles after fluid-phase endocytosis. Mol. Pharmacol. 69 (2006) 1624-1632
44. Allen M.R., and Burr D.B. Mandible matrix necrosis in beagle dogs after 3 years of daily oral bisphosphonate treatment. J. Oral Maxillofac. Surg. 66 (2008) 987-994
45. Wutzl A., Eisenmenger G., Hoffmann M., Czerny C., Moser D., Pietschmann P., et al. Osteonecrosis of the jaws and bisphosphonate treatment in cancer patients. Wien. Klin. Wochenschr. 118 (2006) 473-478
46. Bedogni A., Blandamura S., Lokmic Z., Palumbo C., Ragazzo M., Ferrari F., et al. Bisphosphonate-associated jawbone osteonecrosis: a correlation between imaging techniques and histopathology. Oral Med. Oral Pathol. Oral Radiol. Endodontol. 105 (2008) 358-364
47. Hall V. Actinomyces-gathering evidence of human colonization and infection. Anaerobe 14 (2008) 1-7
48. Costerton J.W., Stewart P.S., and Greenberg E.P. Bacterial biofilms: a common cause of persistent infections. Science 284 (1999) 1318-1322
49. Nair S.P., Meghji S., Wilson M., Reddi K., White P., and Henderson B. Bacterially induced bone destruction: mechanisms and misconceptions. Infect. Immun. 64 (1996) 2371-2380
50. Belibasakis G.N., Bostanci N., Hashim A., Johansson A., Aduse-Opoku J., Curtis M.A., et al. Regulation of RANKL and OPG gene expression in human gingival fibroblasts and periodontal ligament cells by Porphyromonas gingivalis: a putative role of the Arg-gingipains. Microb. Pathog. 43 (2007) 46-53
51. Hewitt R.E., Lissina A., Green A.E., Slay E.S., Price D.A., and Sewell A.K. The bisphosphonate acute phase response: rapid and copious production of proinflammatory cytokines by peripheral blood gamma delta T cells in response to aminobisphosphonates is inhibited by statins. Clin. Exp. Immunol. 139 (2005) 101-111
52. Ishikawa C., Matsuda T., Okudaira T., Tomita M., Kawakami H., Tanaka Y., et al. Bisphosphonate incadronate inhibits growth of human T-cell leukaemia virus type I-infected T-cell lines and primary adult T-cell leukaemia cells by interfering with the mevalonate pathway. Brit. J. Haematol. 136 (2007) 424-432
53. Correia V.D.P., Caldeira C.L., and Marques M.M. Cytotoxicity evaluation of sodium alendronate on cultured human periodontal ligament fibroblasts. Dental Traumatol. 22 (2006) 312-317
54. Hashimoto K., Morishige K.I., Sawada K., Tahara M., Shimizu S., Ogata S., et al. Alendronate suppresses tumor angiogenesis by inhibiting Rho activation of endothelial cells. Biochem. Biophys. Res. Comm. 354 (2007) 478-484
55. Moreira M.S., Katayama E., Bombana A.C., and Marques M.M. Cytotoxicity analysis of alendronate on cultured endothelial cells and subcutaneous tissue. A pilot study. Dent. Traumatol. 21 (2005) 329-335
56. Ribatti D., Maruotti N., Nico B., Longo V., Mangierv D., Vacca A., et al. Clodronate inhibits angiogenesis in vitro and in vivo. Oncol. Rep. 19 (2008) 1109-1112
57. Roelofs A.J., Thompson K., Gordon S., and Rogers M.J. Molecular mechanisms of action of bisphosphonates: current status. Clin. Cancer Res. 12 (2006) 6222S-6230S
58. Reszka A.A., Halasy-Nagy J., and Rodan G.A. Nitrogen-bisphosphonates block retinoblastoma phosphorylation and cell growth by inhibiting the cholesterol biosynthetic pathway in a keratinocyte model for esophageal irritation. Mol. Pharmacol. 59 (2001) 193-202
59. Landesberg R., Cozin M., Cremers S., Woo V., Kousteni S., Sinha S., et al. Inhibition of oral mucosal cell wound healing by bisphosphonates. J. Oral Maxillofac. Surg. 66 (2008) 839-847
60. Ripamonti C.I., Maniezzo M., Campa T., Fagnoni E., Brunelli C., Saibene G., Bareggi C., Ascani L., and Cislaghi E. Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan. Ann. Oncol. (2008)
61. Corso A., Varettoni M., Zappasodi P., Klersy C., Mangiacavalli S., Pica G., et al. A different schedule of zoledronic acid can reduce the risk of the osteonecrosis of the jaw in patients with multiple myeloma. Leukemia 21 (2007) 1545-1548
62. Adornato M.C., Morcos I., and Rozanski J. The treatment of bisphosphonate-associated osteonecrosis of the jaws with bone resection and autologous platelet-derived growth factors. JADA 138 (2007) 971-977
63. Kademani D., Koka S., Lacy M.Q., and Rajkumar S.V. Primary surgical therapy for osteonecrosis of the jaw secondary to bisphosphonate therapy. Mayo. Clin. Proc. 81 (2006) 1100-1103
64. Ibrahim T., Barbanti F., Giorgio-Marrano G., Mercatali L., Ronconi S., Vicini C., et al. Osteonecrosis of the jaw in patients with bone metastases treated with bisphosphonates: a retrospective study. Oncologist 13 (2008) 330-336
65. Magopoulos C., Karakinaris G., Telioudis Z., Vahtsevanos K., Dimitrakopoulos I., Antoniadis K., et al. Osteonecrosis of the jaws due to bisphosphonate use. A review of 60 cases and treatment proposals. Amer. J. Otolaryngol. 28 (2007) 158-163